Methods and Results Based on experience in phase II trials, TIMI 9A used a hirudin bolus of 0.6 mg/kg followed by a fixed-dose 96-hour infusion of 0.2 mg/kg per hour. A modified weight-adjusted heparin regimen was used (5000-U bolus and infusion of 1000 U/h for patients <80 kg or 1300 U/h for patients .80 kg) with titration to a target activated partial thromboplastin time (aPTT) of 60 to 90 seconds. Because rates of hemorrhage in both treatment arms were higher than expected, randomization was suspended in TIMI 9A after 757 patients had been enrolled. Intracranial hemorrhage occurred in 1.7% of patients treated with hirudin and 1.9% of those treated with heparin (P=NS). Major spontaneous hemorrhage at a nonintracranial site occurred more frequently in hirudinthan in heparin-treated patients (7.0% versus 3.0%; P=.02), whereas major hemorrhage at instrumented sites was similar (5.2% in both hirudin and heparin groups). Patients who developed a major hemorrhage were older (P<.001) and had
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Conclusions The rate of major spontaneous hemorrhage for both heparin and hirudin in TIMI 9A was higher than that seen in TIMI 5, TIMI 6, and GUSTO 1. This was possibly a result of high levels of anticoagulation at the doses of heparin and hirudin used, low previous estimates of the hemorrhage risk at the doses of hirudin used in TIMI 9A due to the relatively small number of patients receiving that dose in earlier studies, and enrollment of patients at higher risk of hemorrhage. Because a prolonged aPTT was associated with an increased risk of major hemorrhage in both heparin-and hirudin-treated patients, it now appears important to monitor aPTT on a regular basis when using either antithrombin to identify those patients who require downward adjustment of the infusion. TIMI 9B has therefore been configured with a lower hirudin bolus (0.1 mg/kg) and infusion (0.1 mg/kg per hour) and lower heparin infusion (1000 U/h without weight adjustment See p 2147
Methods
Patients with acute MI exhibiting .0.1 mV ST-segment elevation in two or more ECG leads and presenting within 12 hours of the onset of ischemic discomfort were enrolled provided no contraindications to thrombolytic therapy (active bleeding, history of stroke, major surgery within 2 months, blood pressure >190/110 mm Hg despite medical therapy) were present and they were at least 21 years of age (no upper age limit for enrollment). Selection of thrombolytic agent was at the treating physician's discretion and consisted either of front-loaded, weight-adjusted tissue plasminogen activator (TPA; maximum 100 mg) over 90 minutes3 or 1.5 million U streptokinase over 1 hour. Patients received 150 to 325 mg aspirin immediately (followed by daily therapy thereafter) and were randomized to heparin or hirudin in the doses discussed subsequently. A single lot of porcine heparin (Elkins-Scinn) was used throughout the trial.
The primary efficacy end point of the trial was ascertained at 30 days and consisted of the occurrence of at least one of the following: death, recurrent MI, development of congestive heart failure/cardiogenic shock, or left ventricular ejection fraction <40%. The primary safety end point was the occurrence of major hemorrhage, defined as either an intracranial hemorrhage or overt hemorrhage, in association with an absolute reduction in hematocrit of 15%, or anaphylaxis. The latter element of the primary safety end point was included because recombinant desulfatohirudin is a nonhuman peptide, and the possibility exists that a patient could experience an anaphylactic reaction if they had prior leech or hirudin exposure.
Doses of Study Drugs and Monitoring of Activated Partial Thromboplastin Time in TIMI 9A
The doses of the study drugs in TIMI 9A were selected based on data from phase II clinical trials. Hematologic data from TIMI 5 (TPA plus heparin/hirudin) and TIMI 6 (streptokinase plus heparin/hirudin) showed a dose-related increase in the median activated partial thromboplastin time (aPTT) values in hirudin-treated patients that, in the group with the highest hirudin dose (0.6 mg/kg bolus and 0.2 mg/kg per hour infusion), was approximately 15 to 25 seconds greater than that in heparin-treated patients (5000-U bolus, 1000-U/h infusion) between 24 and 96 hours after thrombolysis (85 to 90 seconds versus 65 to 70 seconds).4,5 In the TIMI 5 trial, aPTT measurements were performed locally at each center using a Ciba-Coming 512 bedside monitor; in TIMI 6, aPTT measurements were performed locally, either with a Ciba-Corning 512 bedside monitor or hospital coagulation laboratory. In both the TIMI 5 and TIMI 6 trials, no intracranial hemorrhages occurred in any of the hirudin-dose groups; a single intracranial hemorrhage occurred in the heparin group of the TIMI 5 trial (1 of 86 patients in TIMI 5, 1.2%).4'5 The incidence of major spontaneous hemorrhage at a nonintracranial site was not different between heparin-treated patients and those treated with any of the doses of hirudin in TIMI 5 and TIMI 6, nor was there any evidence of a trend toward an increased rate of major spontaneous hemorrhagic events with ascending doses of hirudin.4'5 In the combined TIMI 5-TIMI 6 data set of 437 patients, a total of 11 (2.5%) major spontaneous hemorrhages (intracranial and nonintracranial) occurred collectively among all treatment groups. These data therefore suggested that the higher aPTT values and hence higher level of anticoagulation seen with increased doses of hirudin could be maintained without a resultant increase in the risk of major spontaneous hemorrhagic episodes.
Although TIMI 5 and TIMI 6 were pilot trials and as such not designed with sufficient power to detect significant differences in efficacy between heparin and hirudin, both trials revealed encouraging trends of superiority of hirudin over heparin.4'5 Hirudin-treated patients experienced higher rates of patency of the infarct-related artery in TIMI 5 and tended to have lower rates of death, nonfatal reinfarction, and congestive heart failure by hospital discharge with increasing dosage in TIMI 6.4,5
Based on the initial experience with hirudin in patients treated with TPA or streptokinase in the TIMI 5 and TIMI 6 trials, the TIMI 9A trial was designed with a hirudin bolus of 0.6 mg/kg followed by a 96-hour infusion at a dose of 0.2 mg/kg per hour. Because of the relative stability of the antithrombotic action of hirudin compared with heparin as measured by the aPTT, the dose of hirudin in TIMI 9A was fixed and not adjusted in response to aPTT measurements. 6, 7 In an effort to examine whether hirudin could be safely administered to patients with a less restricted clinical profile than in the TIMI 5 and 6 pilot studies, broader enrollment criteria were used in TIMI 9A, including a more elevated baseline creatinine level. However, in view of the clearance of hirudin predominantly through the renal route, during the first 4 months of the trial, infusion of study drug was discontinued in patients whose serum creatinine rose to .2.5 mg/dL; during the second 4 months of the trial, it was restricted further to >2.0 mg/dL. Because the aPTT values in patients receiving heparin infusions of 1000 U/h in TIMI 5 and TIMI 6 were often below the target range and experience in GUSTO 1 and TIMI 4 suggested that weight adjustment of the heparin dose was required to maintain the aPTT in the desired range,8'9 a modified weight-adjusted heparin regimen was used in TIMI 9A (1000 U/h for patients <80 kg and 1300 U/h for patients >80 kg) with titration to a target aPTT value that was approximately 2 to 3 times control (60 to 90 seconds) in most laboratories. All aPTT measurements were performed locally at the enrolling center using either a hospital anticoagulation laboratory or a bedside aPTT monitoring system. The same method of aPTT measurement (eg, laboratory versus bedside) was used for all patients enrolled at each center. For aPTT values that exceeded the upper range of measurement at the local center (between 100 and 200 seconds for most centers), a censored aPTT value was recorded. The heparin infusions were adjusted using a modified version of the nomogram published by Hirsh and colleagues.'0
Safety Monitoring Procedures in TIMI 9A
Enrollment of patients in TIMI 9A commenced in August 1993. As part of the regular safety monitoring of the trial, detailed data on the rate of major hemorrhage were summarized from case report forms entered at the Data Coordinating Center and compared with reported rates in contemporary trials of thrombolytic therapy for acute MI.3-5s11-14
Results

Safety Observations
Close monitoring was carried out by the Operations Committee, who were blinded to treatment assignment, on a twice-monthly basis. When 311 patients were in the database, the rate of major hemorrhage appeared to stabilize at approximately 10%, which was higher than expected. The chairman of the Data Safety Monitoring Board (DSMB) was then requested to review unblinded safety data. The full DSMB subsequently reviewed data on a "locked cohort" of 394 patients for whom 100% of data was available, as well as selected safety data on an additional 123 patients. The board also received informal reports from the chairman of the DSMB of the GUSTO 2 trial, which used identical antithrombin regimens. On April 8, 1994 , the DSMB recommended suspension of randomization in TIMI 9A and consideration of reducing the doses of both heparin and hirudin.
At the time of the DSMB recommendation, 88 centers in North America and two in the United Kingdom had enrolled 757 patients into TIMI 9A. Safety data on all 757 patients have been analyzed and are summarized in this report. The baseline clinical characteristics of the two treatment groups analyzed were well balanced at enrollment (Table 1 ). In nearly 85% of patients, the thrombolytic administered was TPA. The data on the 713 patients (94%) who received at least some q(iantity of the study drug are presented in Tables 2 and 3, analyzed according to the treatment group to which patients were assigned.
Major Hemorrhagic Events
Intracranial hemorrhage occurred in 6 (1.7%) of the Of the 85 major hemorrhagic events that developed during the trial, 33 (39%) occurred within 24 hours of the initiation of thrombolysis and study drug treatment, whereas the remaining 52 occurred after 24 hours. Hirudin-treated patients experienced major hemorrhages earlier in the course of treatment than heparintreated patients (mean, 76 hours versus 98 hours; P=NS). A total of 167 patients (23%) required permanent discontinuation of the study drug. In both drug groups, the development of a major hemorrhage was the principal reason for discontinuation of study drug (16.2% of hirudin patients versus 10.9% of heparin patients; P=.04). Study drug was permanently discontinued in a greater proportion of patients receiving TPA randomized to hirudin versus heparin (27.2% versus 17.9%; P=.008). Of the patients receiving streptokinase, 28.4% required permanent discontinuation of the study drug, but no significant difference was seen between heparin and hirudin.
Patients who experienced a major hemorrhage during the trial were significantly older than those who did not develop a hemorrhagic event (mean, 68 years versus 61 years; P<.001) ( Table 3) . Although only 11.7% of the patients enrolled in the trial were over age 75, they had an increased relative risk (RR) of sustaining a major hirudin groups (RR, 2.8; P=.003). Heparin patients who developed a major hemorrhage had a lower body weight (P<.001) and were more often women (P=.03).
Hirudin-treated patients with a major hemorrhage had a significantly higher serum creatinine level at enrollment compared with those hirudin patients who did not experience a major hemorrhage (P<.001) (Table 3). Although patients without a history of renal dysfunction but whose baseline creatinine was >1.5 mg/dL represented only 7.3% and 5.5% of the heparin and hirudin groups, respectively (Table 3) , they experienced major hemorrhages significantly more frequently than those patients whose baseline creatinine was c 1.5 mg/dL. For patients with a baseline creatinine >1.5 mg/dL, the RR of a major hemorrhage was 2.4 in the heparin group (P=.04) and 3.0 in the hirudin group (P=.009). Of the 6 patients in the heparin group who had a major hemorrhage and a baseline creatinine > 1.5 mg/dL, 3 experienced a major spontaneous hemorrhage at a nonintracranial site and 3 had a major hemorrhage at an instrumented site. Of the 7 patients in the hirudin group who had a major hemorrhage and a baseline creatinine > 1.5 mg/dL, there was one intracranial hemorrhage, four major spontaneous hemorrhages at a nonintracranial site, and one major hemorrhage at an instrumented site.
The median aPTT values tended to be higher at 12 hours after thrombolysis in the group who sustained a major hemorrhage compared with those who did not (100 seconds versus 85 seconds; P=.001) ( Table 3 ). In addition, the 75th percentile of the aPTT values measured throughout the course of study drug treatment tended to be higher in those patients who developed major hemorrhages, although this did not achieve statistical significance.
No episodes of anaphylaxis occurred in the trial.
Discussion
The rate of major spontaneous hemorrhage for heparin and hirudin (both with and without intracranial hemorrhage) in TIMI 9A was higher than that seen in TIMI 5, TIMI 6, and GUSTO 1.3-5 Possible explanations for these differences are as follows.
(1) Higher levels of anticoagulation were achieved in TIMI 9A compared with previous trials. Prior clinical studies suggested that heavier patients require a greater hourly infusion rate of heparin to avoid subtherapeutic aPTT values.89 In an attempt to circumvent this problem, the dose of heparin used in TIMI 9A was increased (infusion of 1000 U/h for patients <80 kg or 1300 U/h for those .80 kg) compared with that used in TIMI 5 and TIMI 6 (infusion of 1000 U/h without weight adjustment). The safety of higher doses of heparin in patients receiving thrombolytic therapy and aspirin for acute MI has not been rigorously established. The observations in TIMI 9A suggest that a simple "two-level" adjustment of heparin dichotomized at a patient weight of 80 kg is associated with excessive rates of hemorrhage.
(2) The risk of major hemorrhage associated with the dose of hirudin used in TIMI 9A may have been underestimated because of the relatively small number of patients receiving that dose in earlier studies.45 (3) The patients enrolled in TIMI 9A were at higher risk of hemorrhage than those in the earlier phase II hemorrhage in both the heparin (RR, 1.8; P=.16) and studies. The upper age limit for enrollment in TIMI 5 thrombolytics is to achieve an optimal plateau aPTT level without exceeding it during the acute phase and to maintain it during the course of the infusion over several days. Pharmacokinetic modeling as well as clinical experience was therefore used to reconfigure TIMI 9 (now referred to as TIMI 9B) with a lower hirudin bolus (0.1 mg/kg) and infusion (0.1 mg/kg per hour) and a lower heparin infusion (1000 U/h without weight adjustment).4-7,15 Infusions of both antithrombins will be titrated to a slightly reduced aPTT target range of 55 to 85 seconds in TIMI 9B.
Because the rate of hemorrhage in both treatment arms was higher than expected, resulting in permanent discontinuation of the study drug in 23% of patients, it appears that the doses of both heparin and hirudin were too high in TIMI 9A. It therefore would be premature to draw any conclusions about the relative safety and efficacy of lower doses of heparin and hirudin when used with TPA or streptokinase and aspirin. The modified design of TIMI 9B will permit continued testing of whether the potential advantages of hirudin (direct antithrombin, inhibition of clot-bound thrombin, reliable pharmacodynamic response,6 and inhibition of platelet deposition17) over heparin will translate into improved clinical outcome in patients with acute MI receiving thrombolytic therapy.
